Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction - PubMed (original) (raw)
Clinical Trial
. 2011 Aug 24;3(97):97ra80.
doi: 10.1126/scitranslmed.3002716.
Samantha Cooray, Kimberly C Gilmour, Kathryn L Parsley, Fang Zhang, Stuart Adams, Emma Bjorkegren, Jinhua Bayford, Lucinda Brown, E Graham Davies, Paul Veys, Lynette Fairbanks, Victoria Bordon, Theoni Petropoulou, Christine Kinnon, Adrian J Thrasher
Affiliations
- PMID: 21865538
- DOI: 10.1126/scitranslmed.3002716
Clinical Trial
Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction
H Bobby Gaspar et al. Sci Transl Med. 2011.
Erratum in
- Sci Transl Med. 2013 Jan 16;5(168):168er1. Petropolou, Theoni [corrected to Petropoulou, Theoni]
Abstract
Genetic defects in the purine salvage enzyme adenosine deaminase (ADA) lead to severe combined immunodeficiency (SCID) with profound depletion of T, B, and natural killer cell lineages. Human leukocyte antigen-matched allogeneic hematopoietic stem cell transplantation (HSCT) offers a successful treatment option. However, individuals who lack a matched donor must receive mismatched transplants, which are associated with considerable morbidity and mortality. Enzyme replacement therapy (ERT) for ADA-SCID is available, but the associated suboptimal correction of immunological defects leaves patients susceptible to infection. Here, six children were treated with autologous CD34-positive hematopoietic bone marrow stem and progenitor cells transduced with a conventional gammaretroviral vector encoding the human ADA gene. All patients stopped ERT and received mild chemotherapy before infusion of gene-modified cells. All patients survived, with a median follow-up of 43 months (range, 24 to 84 months). Four of the six patients recovered immune function as a result of engraftment of gene-corrected cells. In two patients, treatment failed because of disease-specific and technical reasons: Both restarted ERT and remain well. Of the four reconstituted patients, three remained off enzyme replacement. Moreover, three of these four patients discontinued immunoglobulin replacement, and all showed effective metabolic detoxification. All patients remained free of infection, and two cleared problematic persistent cytomegalovirus infection. There were no adverse leukemic side effects. Thus, gene therapy for ADA-SCID is safe, with effective immunological and metabolic correction, and may offer a viable alternative to conventional unrelated donor HSCT.
Similar articles
- Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
Otsu M, Yamada M, Nakajima S, Kida M, Maeyama Y, Hatano N, Toita N, Takezaki S, Okura Y, Kobayashi R, Matsumoto Y, Tatsuzawa O, Tsuchida F, Kato S, Kitagawa M, Mineno J, Hershfield MS, Bali P, Candotti F, Onodera M, Kawamura N, Sakiyama Y, Ariga T. Otsu M, et al. J Clin Immunol. 2015 May;35(4):384-98. doi: 10.1007/s10875-015-0157-1. Epub 2015 Apr 15. J Clin Immunol. 2015. PMID: 25875699 - Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.
Ferrua F, Brigida I, Aiuti A. Ferrua F, et al. Curr Opin Allergy Clin Immunol. 2010 Dec;10(6):551-6. doi: 10.1097/ACI.0b013e32833fea85. Curr Opin Allergy Clin Immunol. 2010. PMID: 20966749 Review. - Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.
Cicalese MP, Ferrua F, Castagnaro L, Rolfe K, De Boever E, Reinhardt RR, Appleby J, Roncarolo MG, Aiuti A. Cicalese MP, et al. Mol Ther. 2018 Mar 7;26(3):917-931. doi: 10.1016/j.ymthe.2017.12.022. Epub 2018 Jan 4. Mol Ther. 2018. PMID: 29433935 Free PMC article. - Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Cicalese MP, Ferrua F, Castagnaro L, Pajno R, Barzaghi F, Giannelli S, Dionisio F, Brigida I, Bonopane M, Casiraghi M, Tabucchi A, Carlucci F, Grunebaum E, Adeli M, Bredius RG, Puck JM, Stepensky P, Tezcan I, Rolfe K, De Boever E, Reinhardt RR, Appleby J, Ciceri F, Roncarolo MG, Aiuti A. Cicalese MP, et al. Blood. 2016 Jul 7;128(1):45-54. doi: 10.1182/blood-2016-01-688226. Epub 2016 Apr 29. Blood. 2016. PMID: 27129325 Free PMC article. Clinical Trial. - How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).
Kohn DB, Gaspar HB. Kohn DB, et al. J Clin Immunol. 2017 May;37(4):351-356. doi: 10.1007/s10875-017-0373-y. Epub 2017 Feb 14. J Clin Immunol. 2017. PMID: 28194615 Review.
Cited by
- Functional genomics in inborn errors of immunity.
Hurabielle C, LaFlam TN, Gearing M, Ye CJ. Hurabielle C, et al. Immunol Rev. 2024 Mar;322(1):53-70. doi: 10.1111/imr.13309. Epub 2024 Feb 8. Immunol Rev. 2024. PMID: 38329267 Review. - Advances in gene therapy for inborn errors of immunity.
Ott de Bruin LM, Lankester AC, Staal FJT. Ott de Bruin LM, et al. Curr Opin Allergy Clin Immunol. 2023 Dec 1;23(6):467-477. doi: 10.1097/ACI.0000000000000952. Epub 2023 Oct 13. Curr Opin Allergy Clin Immunol. 2023. PMID: 37846903 Free PMC article. Review. - Clinical applications of gene therapy for rare diseases: A review.
Papaioannou I, Owen JS, Yáñez-Muñoz RJ. Papaioannou I, et al. Int J Exp Pathol. 2023 Aug;104(4):154-176. doi: 10.1111/iep.12478. Epub 2023 May 13. Int J Exp Pathol. 2023. PMID: 37177842 Free PMC article. Review. - Correcting inborn errors of immunity: From viral mediated gene addition to gene editing.
Castiello MC, Ferrari S, Villa A. Castiello MC, et al. Semin Immunol. 2023 Mar;66:101731. doi: 10.1016/j.smim.2023.101731. Epub 2023 Feb 28. Semin Immunol. 2023. PMID: 36863140 Free PMC article. Review. - Gene therapy for inborn errors of immunity: past, present and future.
Fischer A. Fischer A. Nat Rev Immunol. 2023 Jun;23(6):397-408. doi: 10.1038/s41577-022-00800-6. Epub 2022 Nov 25. Nat Rev Immunol. 2023. PMID: 36434109 Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials